MedTrace Logo

Thalidomide-Dexamethasone for Multiple Myeloma

NCT00038090 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2018-10-31

No results posted yet for this study

Summary

Objective is to assess the activity of the combination of thalidomide and dexamethasone in patients with previously untreated multiple myeloma.

Conditions

Interventions

DRUG

Thalidomide

100 mg capsules by mouth daily each evening

DRUG

Dexamethasone

20 mg/m\^2 taken by mouth each morning on days 1-4, 9-12 and 17-20.

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Donna M Weber, M.D. · UT MD Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-06-30
Primary Completion
2005-05-31
Completion
2005-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00038090 on ClinicalTrials.gov